Research programme: traditional Chinese medicinal therapeutics - ChipscreenAlternative Names: CS 900210; CS 90034602; CS 90050105; CS 90060103
Latest Information Update: 15 Aug 2007
At a glance
- Originator Chipscreen Biosciences
- Mechanism of Action Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Cancer; Osteoporosis; Type 2 diabetes mellitus
Most Recent Events
- 20 Jul 2004 Preclinical trials in Osteoporosis in China (unspecified route)
- 20 Jul 2004 Preclinical trials in Type-2 diabetes mellitus in China (unspecified route)
- 20 Jul 2004 Preclinical trials in Cancer in China (unspecified route)